{
  "parsed": [
    {
      "model": "claude",
      "raw": "\n\n\u2500\u2500\u2500 SECTION 1: DECOMPOSITION \u2500\u2500\u2500\n\n**Sub-question 1:** Do CBD/erastin/DIDS occupy overlapping or distinct VDAC1 binding sites, and what physicochemical logic governs site selection?\n\n**Sub-question 2:** Does the VDAC2 N-terminal 11-residue extension create a druggable structural divergence, or is the difference too conformationally dynamic to exploit?\n\n**Sub-question 3:** Does the gating-domain vs. conductance-domain pharmacological dichotomy hold quantitatively \u2014 i.e., do helix-site ligands produce graded modulation while barrel-site ligands produce binary conductance block?\n\n**Key variables:** Ligand logP (membrane partitioning), VDAC N-terminal conformational dynamics, pore electrostatics (K12/K20 accessibility), HK-II/BAK occupancy as competitive modulators of ligand access.\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS \u2500\u2500\u2500\n\n**CLAIM:** CBD, erastin, and DIDS engage three structurally and mechanistically distinct VDAC1 sites \u2014 lipid-protein interface (CBD), interior barrel wall \u03b214-19 (erastin), and pore vestibule lysines (DIDS) \u2014 with no significant competitive overlap.\n**TYPE:** 1\n**CONFIDENCE:** 0.78\n**MECHANISM:** Site selection is governed by ligand physicochemistry: CBD's logP ~6.3 confines it to the membrane-embedded helix groove; erastin's moderate polarity (logP ~2.2) accesses a partially desolvated barrel cavity via the aqueous pore; DIDS's bis-isothiocyanate groups undergo irreversible nucleophilic attack by K12/K20.\n**FALSIFIABLE BY:** Competition binding assays showing CBD displaces erastin, or a cryo-EM structure placing CBD inside the barrel lumen rather than at the lipid interface.\n\n**CLAIM:** VDAC2's 11-residue N-terminal extension sterically remodels the helix-groove pocket, reducing CBD-type ligand affinity by \u226510-fold and enabling VDAC1-selective design without relying solely on cofactor competition.\n**TYPE:** 2\n**CONFIDENCE:** 0.55\n**MECHANISM:** The extended VDAC2 N-terminus occupies space equivalent to CBD's binding groove in VDAC1, creating a steric filter; molecular dynamics suggest this extension samples conformations that cap the vestibule.\n**FALSIFIABLE BY:** VDAC2-\u039411 truncation mutant restoring CBD binding to VDAC1-equivalent Kd; or NMR/HDX-MS showing the VDAC2 extension is fully disordered and does not contact the helix-groove region.\n\n**CLAIM:** At clinical concentrations (1\u201310 \u03bcM), CBD achieves only ~30\u201350% VDAC1 occupancy (Kd = 11 \u03bcM), producing graded gating modulation rather than channel ablation \u2014 this partial occupancy is pharmacologically essential for tolerability.\n**TYPE:** 1\n**CONFIDENCE:** 0.80\n**MECHANISM:** Simple Langmuir occupancy: at [CBD] = 5 \u03bcM and Kd = 11 \u03bcM, fractional occupancy = 5/(5+11) \u2248 0.31; at 10 \u03bcM, \u2248 0.48. This sub-saturating engagement preserves mitochondrial ATP/ADP flux while modulating calcium and metabolite gating.\n**FALSIFIABLE BY:** Demonstrating steep Hill coefficient (nH > 2) indicating cooperative binding that shifts occupancy curve, or showing VDAC1-independent mechanism dominates CBD's mitochondrial effects.\n\n**CLAIM:** Barrel-wall ligands (erastin class) produce near-binary conductance block (Hill coefficient \u22651.5, steep dose-response), while helix-site ligands (CBD class) produce graded allosteric modulation (Hill coefficient ~1, shallow dose-response), representing pharmacologically distinct classes.\n**TYPE:** 2\n**CONFIDENCE:** 0.60\n**MECHANISM:** Pore occlusion is geometrically cooperative (partial block destabilizes ion flow nonlinearly); helix-site binding shifts conformational equilibria gradually.\n**FALSIFIABLE BY:** Electrophysiology showing erastin produces graded, shallow-slope conductance reduction identical to CBD, or showing CBD induces complete channel closure at saturating concentrations.\n\n\u2500\u2500\u2500 SECTION 3: UNKNOWNS \u2500\u2500\u2500\n\n- No high-resolution co-structure of CBD-VDAC1 or erastin-VDAC1 exists; all binding site assignments are inferred from mutagenesis, docking, and crosslinking.\n- VDAC2 N-terminal extension structure is unresolved \u2014 it may be disordered and irrelevant to pocket geometry.\n- Whether HK-II binding allosterically reshapes the CBD or erastin site is untested.\n- Membrane lipid composition (cardiolipin, cholesterol) likely modulates",
      "claims": [
        {
          "statement": "CBD, erastin, and DIDS engage three structurally and mechanistically distinct VDAC1 sites \u2014 lipid-protein interface (CBD), interior barrel wall \u03b214-19 (erastin), and pore vestibule lysines (DIDS) \u2014 with no significant competitive overlap.",
          "type": 1,
          "confidence": 0.78,
          "mechanism": "Site selection is governed by ligand physicochemistry: CBD's logP ~6.3 confines it to the membrane-embedded helix groove; erastin's moderate polarity (logP ~2.2) accesses a partially desolvated barrel cavity via the aqueous pore; DIDS's bis-isothiocyanate groups undergo irreversible nucleophilic attack by K12/K20.",
          "falsifiable_by": "Competition binding assays showing CBD displaces erastin, or a cryo-EM structure placing CBD inside the barrel lumen rather than at the lipid interface."
        },
        {
          "statement": "VDAC2's 11-residue N-terminal extension sterically remodels the helix-groove pocket, reducing CBD-type ligand affinity by \u226510-fold and enabling VDAC1-selective design without relying solely on cofactor competition.",
          "type": 2,
          "confidence": 0.55,
          "mechanism": "The extended VDAC2 N-terminus occupies space equivalent to CBD's binding groove in VDAC1, creating a steric filter; molecular dynamics suggest this extension samples conformations that cap the vestibule.",
          "falsifiable_by": "VDAC2-\u039411 truncation mutant restoring CBD binding to VDAC1-equivalent Kd; or NMR/HDX-MS showing the VDAC2 extension is fully disordered and does not contact the helix-groove region."
        },
        {
          "statement": "At clinical concentrations (1\u201310 \u03bcM), CBD achieves only ~30\u201350% VDAC1 occupancy (Kd = 11 \u03bcM), producing graded gating modulation rather than channel ablation \u2014 this partial occupancy is pharmacologically essential for tolerability.",
          "type": 1,
          "confidence": 0.8,
          "mechanism": "Simple Langmuir occupancy: at [CBD] = 5 \u03bcM and Kd = 11 \u03bcM, fractional occupancy = 5/(5+11) \u2248 0.31; at 10 \u03bcM, \u2248 0.48. This sub-saturating engagement preserves mitochondrial ATP/ADP flux while modulating calcium and metabolite gating.",
          "falsifiable_by": "Demonstrating steep Hill coefficient (nH > 2) indicating cooperative binding that shifts occupancy curve, or showing VDAC1-independent mechanism dominates CBD's mitochondrial effects."
        },
        {
          "statement": "Barrel-wall ligands (erastin class) produce near-binary conductance block (Hill coefficient \u22651.5, steep dose-response), while helix-site ligands (CBD class) produce graded allosteric modulation (Hill coefficient ~1, shallow dose-response), representing pharmacologically distinct classes.",
          "type": 2,
          "confidence": 0.6,
          "mechanism": "Pore occlusion is geometrically cooperative (partial block destabilizes ion flow nonlinearly); helix-site binding shifts conformational equilibria gradually.",
          "falsifiable_by": "Electrophysiology showing erastin produces graded, shallow-slope conductance reduction identical to CBD, or showing CBD induces complete channel closure at saturating concentrations. \u2500\u2500\u2500"
        }
      ]
    },
    {
      "model": "mistral",
      "raw": "```\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\nSECTION 1: DECOMPOSITION\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n1. **Binding site discrimination**: Do CBD, erastin, and DIDS share a VDAC1 site or engage distinct pockets (N-term helix vs. barrel wall vs. pore vestibule)?\n   *Key variables*: Ligand lipophilicity (logP), residue accessibility (solvent-exposed vs. buried), covalent vs. non-covalent binding.\n\n2. **Isoform selectivity drivers**: How do VDAC2\u2019s N-terminal +11aa and BAK-binding interface create steric/electrostatic filters for VDAC1-selective ligands?\n   *Key variables*: N-term conformation (helical vs. unstructured), pore vestibule geometry, cofactor competition (HK-II/BAK).\n\n3. **Pharmacological outcomes**: Does ligand binding to the N-term helix (allosteric) vs. barrel wall (pore block) predict distinct functional effects (gating modulation vs. conductance reduction)?\n   *Key variables*: Voltage-gating kinetics, ion conductance (single-channel recordings), state-dependent binding.\n\n4. **Selectivity feasibility**: Can VDAC2-sparing ligands exploit structural differences (>70% homology) or must selectivity rely on cofactor competition (e.g., BAK displacement)?\n   *Key variables*: Residue-level divergence in binding pockets, cofactor occupancy (HK-II/BAK), ligand affinity ratios (VDAC1/VDAC2).\n\n---\n\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\nSECTION 2: CLAIMS\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n**CLAIM 1**: CBD, erastin, and DIDS bind three distinct VDAC1 sites: CBD at the lipid-protein interface near the N-term helix, erastin in the barrel wall (\u03b214\u201319), and DIDS covalently at pore-facing lysines (K12/K20).\n*TYPE*: 1\n*CONFIDENCE*: 0.85\n*MECHANISM*: CBD\u2019s lipophilicity (logP 6.3) drives partitioning into membrane-adjacent grooves; erastin\u2019s sulfonamide engages polar barrel residues (E73/R15); DIDS\u2019s isothiocyanates react with solvent-accessible lysines.\n*FALSIFIABLE BY*: Cryo-EM showing CBD in the barrel lumen or erastin at the N-term; mutagenesis (K12A/K20A) abolishing DIDS binding without affecting erastin.\n\n**CLAIM 2**: VDAC2\u2019s +11aa N-terminal extension sterically occludes VDAC1-like CBD/erastin sites, enabling >10-fold VDAC1 selectivity at 1\u201311 \u03bcM.\n*TYPE*: 1\n*CONFIDENCE*: 0.75\n*MECHANISM*: The extended N-term in VDAC2 (unstructured/helical) shields the gating domain, reducing ligand access vs. VDAC1\u2019s compact helix.\n*FALSIFIABLE BY*: Chimeric VDAC1/2 constructs (VDAC1 + VDAC2 N-term) showing reduced CBD affinity; cryo-EM of VDAC2 with CBD bound.\n\n**CLAIM 3**: N-term helix ligands (e.g., CBD) act as allosteric gating modulators (EC50 ~11 \u03bcM), while barrel ligands (erastin/DIDS) act as pore blockers (Ki <1 \u03bcM).\n*TYPE*: 1\n*CONFIDENCE*: 0.70\n*MECHANISM*: Hel",
      "claims": [
        {
          "statement": "1**: CBD, erastin, and DIDS bind three distinct VDAC1 sites: CBD at the lipid-protein interface near the N-term helix, erastin in the barrel wall (\u03b214\u201319), and DIDS covalently at pore-facing lysines (K12/K20). *TYPE*: 1 *CONFIDENCE*: 0.85 *MECHANISM*: CBD\u2019s lipophilicity (logP 6.3) drives partitioning into membrane-adjacent grooves; erastin\u2019s sulfonamide engages polar barrel residues (E73/R15); DIDS\u2019s isothiocyanates react with solvent-accessible lysines. *FALSIFIABLE BY*: Cryo-EM showing CBD in the barrel lumen or erastin at the N-term; mutagenesis (K12A/K20A) abolishing DIDS binding without affecting erastin.",
          "type": 2,
          "confidence": 0.5,
          "mechanism": ": CBD\u2019s lipophilicity (logP 6.3) drives partitioning into membrane-adjacent grooves; erastin\u2019s sulfonamide engages polar barrel residues (E73/R15); DIDS\u2019s isothiocyanates react with solvent-accessible lysines.",
          "falsifiable_by": ": Cryo-EM showing CBD in the barrel lumen or erastin at the N-term; mutagenesis (K12A/K20A) abolishing DIDS binding without affecting erastin."
        },
        {
          "statement": "2**: VDAC2\u2019s +11aa N-terminal extension sterically occludes VDAC1-like CBD/erastin sites, enabling >10-fold VDAC1 selectivity at 1\u201311 \u03bcM. *TYPE*: 1 *CONFIDENCE*: 0.75 *MECHANISM*: The extended N-term in VDAC2 (unstructured/helical) shields the gating domain, reducing ligand access vs. VDAC1\u2019s compact helix. *FALSIFIABLE BY*: Chimeric VDAC1/2 constructs (VDAC1 + VDAC2 N-term) showing reduced CBD affinity; cryo-EM of VDAC2 with CBD bound.",
          "type": 2,
          "confidence": 0.5,
          "mechanism": ": The extended N-term in VDAC2 (unstructured/helical) shields the gating domain, reducing ligand access vs. VDAC1\u2019s compact helix.",
          "falsifiable_by": ": Chimeric VDAC1/2 constructs (VDAC1 + VDAC2 N-term) showing reduced CBD affinity; cryo-EM of VDAC2 with CBD bound."
        },
        {
          "statement": "3**: N-term helix ligands (e.g., CBD) act as allosteric gating modulators (EC50 ~11 \u03bcM), while barrel ligands (erastin/DIDS) act as pore blockers (Ki <1 \u03bcM). *TYPE*: 1 *CONFIDENCE*: 0.70 *MECHANISM*: Hel",
          "type": 2,
          "confidence": 0.5,
          "mechanism": ": Hel",
          "falsifiable_by": ""
        }
      ]
    },
    {
      "model": "grok",
      "raw": "\u2500\u2500\u2500 \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\nINDEPENDENT CONSENSUS \u2014 FROM PREVIOUS CYCLE\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nThe following claims showed independent convergence across multiple\nmirrors in the previous cycle. No mirror saw another's output \u2014\nthis convergence emerged independently. Go deeper on these threads:\nexplore mechanisms, quantitative predictions, and falsification conditions.\n\n  [ESTABLISHED] CBD, erastin, and DIDS engage three distinct VDAC1 sites \u2014 CBD at the lipid-protein interface near the N-terminal helix, erastin at an interior barrel wall pocket (\u03b2-strands 14-19 region), and DIDS covalently at pore-facing lysines (K12, K20).\n    MECHANISM: CBD's extreme lipophilicity (logP ~6.3) drives partitioning into membrane-embedded grooves; erastin's moderate polarity accesses a partially buried barrel cavity; DIDS's isothiocyanate groups react irreversibly with solvent-accessible lysines lining the pore vestibule.\n    OVERLAP: 5/5 mirrors | CONFIDENCE: 0.71\n\n  [ESTABLISHED] VDAC2 N-term +11aa sterically occludes VDAC1-like sites (e.g., CBD helix pocket), enabling >10-fold selectivity for VDAC1 agonists at 1-11\u03bcM.\n    MECHANISM: Extended unstructured/helical N-term in VDAC2 shields gating domain, reducing ligand access vs compact VDAC1 helix.\n    OVERLAP: 4/5 mirrors | CONFIDENCE: 0.663\n\n  [REPLICATED] The CBD therapeutic window (1-10 \u03bcM) functionally prioritizes VDAC1 (Kd 11 \u03bcM) over higher-affinity off-targets like TRPV1 (\n    OVERLAP: 3/5 mirrors | CONFIDENCE: 0.65\n\n  [REPLICATED] N-term helix ligands (CBD) act as allosteric gating modulators (EC50~11\u03bcM in therapeutic window); barrel ligands (erastin/DIDS) as pore blockers (Ki<1\u03bcM).\n    MECHANISM: Helix binding stabilizes open/closed states; barrel occlusion directly reduces conductance.\n    OVERLAP: 3/5 mirrors | CONFIDENCE: 0.633\n\n\nSINGULAR THREADS (1 mirror only \u2014 potential novel insights):\n  [SINGULAR] CBD's Kd of 11 \u03bcM at VDAC1 places it near the ceiling of the therapeutic window (1-10 \u03bcM), meaning clinical VDAC1 engagement is partial (~30-50% occupancy), which may explain why CBD modulates rather than ablates mitochondrial function.\n    SOURCE: claude | CONFIDENCE: 0.8\n  [SINGULAR] Ligand binding to the N-terminal helix allosterically modulates VDAC1 voltage gating, whereas binding to the barrel wall directly obstructs ion conductance, representing two distinct pharmacological classes.\n    SOURCE: gemini | CONFIDENCE: 0.75\n  [SINGULAR] VDAC2-sparing design is feasible primarily through the 11-residue N-terminal extension of VDAC2, which sterically remodels the pore vestibule and creates an isoform-specific steric filter \u2014 not solely through cofactor competition.\n    SOURCE: claude | CONFIDENCE: 0.65\n  [SINGULAR] 2**: Erastin binds VDAC1\u2019s inner barrel wall (\u03b2-strands), while DIDS covalently modifies pore vestibule lysines (e.g., K12/K20). **TYPE**: 1 **CONFIDENCE**: 0.75 **MECHANISM**: Erastin\u2019s sulfonamide moiety interacts with polar residues in the barrel (e.g., E73, R15), while DIDS\u2019s anionic groups target solvent-exposed lysines for covalent modification. **FALSIFIABLE BY**: Mutagenesis (e.g., K12A/K20A) abolishing DIDS binding without affecting erastin, or cryo-EM showing erastin in the barrel lumen.\n    SOURCE: mistral | CONFIDENCE: 0.5\n\nOne mirror saw these \u2014 investigate whether they're real. If you find supporting evidence, include them.\n\nNOTE: Previous cycle achieved 65% TYPE 0/1 overlap. Explore mechanisms and quantitative predictions for converged claims. Investigate singular threads for potential novel discoveries.\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nSECTION 1: DECOMPOSITION (max 200 tokens) \u2500\u2500\u2500\nSub-questions: \n1. Distinct binding sites/mechanisms for CBD (N-helix interface), erastin (barrel \u03b214-19), DIDS (pore lysines K12/K20) on VDAC1?\n2. VDAC1-vs-VDAC2 differences (N-term +11aa occlusion, BAK interface) for isoform-selective ligands?\n3. Helix (gating) vs barrel (conductance) sites predicting allosteric modulation vs pore blockade?\n4. VDAC2-sparing feasibility (>70% TM homology) via structure vs cofactors (HK-II/BAK)?\n\nKey variables: Site location (helix/barrel/pore), ligand properties (logP/polarity), N-term length (VDAC1 compact vs VDAC2 extended), homology (70-90% TM), Kd/EC50 (CBD 11\u03bcM), occupancy (f[conc/Kd]), cofactor competition. Relationships: Lipophilicity \u2192 interface binding; N-term extension \u2192 steric exclusion (>10x selectivity); helix binding \u2192 gating shift (allosteric); barrel \u2192 flux block (direct).\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS (max 400 tokens) \u2500\u2500\u2500\nCLAIM: CBD, erastin, DIDS bind distinct VDAC1 sites: CBD at lipid-facing N-helix groove (residues 1-25/\u03b21-2), erastin in barrel lumen (\u03b214-19, E73",
      "claims": [
        {
          "statement": "CBD, erastin, DIDS bind distinct VDAC1 sites: CBD at lipid-facing N-helix groove (residues 1-25/\u03b21-2), erastin in barrel lumen (\u03b214-19, E73",
          "type": 2,
          "confidence": 0.5,
          "mechanism": "",
          "falsifiable_by": ""
        }
      ]
    },
    {
      "model": "gemini",
      "raw": "\u2500\u2500\u2500\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\nINDEPENDENT CONSENSUS \u2014 FROM PREVIOUS CYCLE\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nThe following claims showed independent convergence across multiple\nmirrors in the previous cycle. No mirror saw another's output \u2014\nthis convergence emerged independently. Go deeper on these threads:\nexplore mechanisms, quantitative predictions, and falsification conditions.\n\n  [ESTABLISHED] CBD, erastin, and DIDS engage three distinct VDAC1 sites \u2014 CBD at the lipid-protein interface near the N-terminal helix, erastin at an interior barrel wall pocket (\u03b2-strands 14-19 region), and DIDS covalently at pore-facing lysines (K12, K20).\n    MECHANISM: CBD's extreme lipophilicity (logP ~6.3) drives partitioning into membrane-embedded grooves; erastin's moderate polarity accesses a partially buried barrel cavity; DIDS's isothiocyanate groups react irreversibly with solvent-accessible lysines lining the pore vestibule.\n    OVERLAP: 5/5 mirrors | CONFIDENCE: 0.71\n\n  [ESTABLISHED] VDAC2 N-term +11aa sterically occludes VDAC1-like sites (e.g., CBD helix pocket), enabling >10-fold selectivity for VDAC1 agonists at 1-11\u03bcM.\n    MECHANISM: Extended unstructured/helical N-term in VDAC2 shields gating domain, reducing ligand access vs compact VDAC1 helix.\n    OVERLAP: 4/5 mirrors | CONFIDENCE: 0.663\n\n  [REPLICATED] The CBD therapeutic window (1-10 \u03bcM) functionally prioritizes VDAC1 (Kd 11 \u03bcM) over higher-affinity off-targets like TRPV1 (\n    OVERLAP: 3/5 mirrors | CONFIDENCE: 0.65\n\n  [REPLICATED] N-term helix ligands (CBD) act as allosteric gating modulators (EC50~11\u03bcM in therapeutic window); barrel ligands (erastin/DIDS) as pore blockers (Ki<1\u03bcM).\n    MECHANISM: Helix binding stabilizes open/closed states; barrel occlusion directly reduces conductance.\n    OVERLAP: 3/5 mirrors | CONFIDENCE: 0.633\n\n\nSINGULAR THREADS (1 mirror only \u2014 potential novel insights):\n  [SINGULAR] CBD's Kd of 11 \u03bcM at VDAC1 places it near the ceiling of the therapeutic window (1-10 \u03bcM), meaning clinical VDAC1 engagement is partial (~30-50% occupancy), which may explain why CBD modulates rather than ablates mitochondrial function.\n    SOURCE: claude | CONFIDENCE: 0.8\n  [SINGULAR] Ligand binding to the N-terminal helix allosterically modulates VDAC1 voltage gating, whereas binding to the barrel wall directly obstructs ion conductance, representing two distinct pharmacological classes.\n    SOURCE: gemini | CONFIDENCE: 0.75\n  [SINGULAR] VDAC2-sparing design is feasible primarily through the 11-residue N-terminal extension of VDAC2, which sterically remodels the pore vestibule and creates an isoform-specific steric filter \u2014 not solely through cofactor competition.\n    SOURCE: claude | CONFIDENCE: 0.65\n  [SINGULAR] 2**: Erastin binds VDAC1\u2019s inner barrel wall (\u03b2-strands), while DIDS covalently modifies pore vestibule lysines (e.g., K12/K20). **TYPE**: 1 **CONFIDENCE**: 0.75 **MECHANISM**: Erastin\u2019s sulfonamide moiety interacts with polar residues in the barrel (e.g., E73, R15), while DIDS\u2019s anionic groups target solvent-exposed lysines for covalent modification. **FALSIFIABLE BY**: Mutagenesis (e.g., K12A/K20A) abolishing DIDS binding without affecting erastin, or cryo-EM showing erastin in the barrel lumen.\n    SOURCE: mistral | CONFIDENCE: 0.5\n\nOne mirror saw these \u2014 investigate whether they're real. If you find supporting evidence, include them.\n\nNOTE: Previous cycle achieved 65% TYPE 0/1 overlap. Explore mechanisms and quantitative predictions for converged claims. Investigate singular threads for potential novel discoveries.\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nSECTION 1: DECOMPOSITION (max 200 tokens) \u2500\u2500\u2500\n\n1.  **Site-Specific Pharmacology:** Do the distinct binding sites of CBD (N-terminal interface), erastin (barrel interior), and DIDS (pore vestibule) define functionally separate classes of VDAC modulators (allosteric vs. pore block)?\n2.  **Isoform Selectivity Determinants:** How does the VDAC2 N-terminal extension (+11 residues) quantitatively impact ligand affinity, and can this structural feature be exclusively targeted for VDAC2-sparing compound design?\n3.  **Therapeutic Occupancy:** Given CBD's Kd for VDAC1 (11 \u03bcM) and its off-targets (e.g., TRPV1, 2 \u03bcM) relative to its therapeutic window (1-10 \u03bcM), what is the predicted fractional occupancy of each target *in vivo*, and what does this imply about its primary mechanism of action?\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS (max 400 tokens) \u2500\u2500\u2500\n\nCLAIM: VDAC1 ligand binding sites define two distinct pharmacological classes: (1) N-terminal helix binders (e.g., CBD) are allosteric modulators of voltage-gating, and (2) Barrel-occluding ligands (e.g., erastin, DIDS) are direct conductance blockers.\nTYPE: 1\nCONFIDENCE: 0.9\nMECHANISM: N-terminal helix binding alters the energy landscape of helix displacement, thus modulating voltage-dependent gating, while barrel binding physically obstructs the ion conduction pathway, reducing maximal current.\nFALSIFIABLE BY: A patch-clamp experiment showing a CBD analog that blocks maximal conductance without shifting the V-1/2 of gating, or an erastin analog that shifts V-1/2 without reducing maximal conductance.\n\nCLAIM: The VDAC2 N-terminal extension sterically hinders the VDAC1-like CBD binding pocket, reducing CBD affinity by at least an order of magnitude (predicted VDAC2 Kd > 100 \u03bcM).\nTYPE: 1\nCONFIDENCE: 0.85\nMECHANISM: The additional 11 residues of VDAC2 form a flexible \"lid\" over the pore vestibule, creating a steric and electrostatic barrier that prevents CBD from accessing the hydrophobic groove at the N-terminal helix/barrel interface.\nFALSIFIABLE BY: Isothermal titration calorimetry (ITC) measurement showing a CBD_VDAC2_Kd < 20 \u03bcM, or a cryo-EM structure of the VDAC2-CBD complex showing a binding pose similar to VDAC1.\n\nCLAIM: Within its therapeutic window (1-10 \u03bcM), CBD achieves only partial VDAC1 occupancy (~30-48%) while achieving near-saturating occupancy of higher-affinity off-targets like TRPV1 (~71-83%).\nTYPE: 1\nCONFIDENCE: 0.95\nMECHANISM: Based on the Michaelis-Menten binding equation ([L]/([L]+Kd)), a plasma concentration of 5 \u03bcM CBD results in ~31% VDAC1 occupancy (5/(5+11)) but ~71% TRPV1 occupancy (5/(5+2)).\nFALSIFIABLE BY: In situ cellular thermal shift assays (CETSA) in a relevant cell line demonstrating that VDAC1 stabilization by CBD is more pronounced than TRPV1 stabilization at therapeutic concentrations.\n\n\u2500\u2500\u2500 SECTION 3: UNKNOWNS (max 150 tokens) \u2500\u2500\u2500\n\n1.  **VDAC2 N-terminal Conformation:** The precise structure and dynamics of the VDAC2 N-terminal extension in a lipid bilayer are unknown. Is it a disordered coil or a stable helix, and does its conformation change with voltage or cofactor binding (e.g., BAK)?\n2.  **BAK Interface Allostery:** It is unknown if ligand binding to the BAK-binding interface (e.g., \u03b2-strands 2-4) can allosterically modulate the N-terminal gating helix, representing a third, unexploited pharmacological site.\n3.  **Lipid Environment Effects:** The reported Kd values are from varied in vitro systems. How the specific lipid composition of the outer mitochondrial membrane (e.g., cardiolipin content) alters the binding affinities of lipophilic drugs like CBD for VDAC isoforms is not quantified.\n\n\u2500\u2500\u2500 SECTION 4: NEXT STEP (max 50 tokens) \u2500\u2500\u2500\n\nDetermine comparative cryo-EM structures of full-length VDAC1 and VDAC2 in cardiolipin-containing nanodiscs, both apo and complexed with CBD, to resolve the structural basis of isoform-selective binding.",
      "claims": [
        {
          "statement": "VDAC1 ligand binding sites define two distinct pharmacological classes: (1) N-terminal helix binders (e.g., CBD) are allosteric modulators of voltage-gating, and (2) Barrel-occluding ligands (e.g., erastin, DIDS) are direct conductance blockers.",
          "type": 1,
          "confidence": 0.9,
          "mechanism": "N-terminal helix binding alters the energy landscape of helix displacement, thus modulating voltage-dependent gating, while barrel binding physically obstructs the ion conduction pathway, reducing maximal current.",
          "falsifiable_by": "A patch-clamp experiment showing a CBD analog that blocks maximal conductance without shifting the V-1/2 of gating, or an erastin analog that shifts V-1/2 without reducing maximal conductance."
        },
        {
          "statement": "The VDAC2 N-terminal extension sterically hinders the VDAC1-like CBD binding pocket, reducing CBD affinity by at least an order of magnitude (predicted VDAC2 Kd > 100 \u03bcM).",
          "type": 1,
          "confidence": 0.85,
          "mechanism": "The additional 11 residues of VDAC2 form a flexible \"lid\" over the pore vestibule, creating a steric and electrostatic barrier that prevents CBD from accessing the hydrophobic groove at the N-terminal helix/barrel interface.",
          "falsifiable_by": "Isothermal titration calorimetry (ITC) measurement showing a CBD_VDAC2_Kd < 20 \u03bcM, or a cryo-EM structure of the VDAC2-CBD complex showing a binding pose similar to VDAC1."
        },
        {
          "statement": "Within its therapeutic window (1-10 \u03bcM), CBD achieves only partial VDAC1 occupancy (~30-48%) while achieving near-saturating occupancy of higher-affinity off-targets like TRPV1 (~71-83%).",
          "type": 1,
          "confidence": 0.95,
          "mechanism": "Based on the Michaelis-Menten binding equation ([L]/([L]+Kd)), a plasma concentration of 5 \u03bcM CBD results in ~31% VDAC1 occupancy (5/(5+11)) but ~71% TRPV1 occupancy (5/(5+2)).",
          "falsifiable_by": "In situ cellular thermal shift assays (CETSA) in a relevant cell line demonstrating that VDAC1 stabilization by CBD is more pronounced than TRPV1 stabilization at therapeutic concentrations. \u2500\u2500\u2500"
        }
      ]
    },
    {
      "model": "deepseek",
      "raw": "\u2500\u2500\u2500\n**SECTION 1: DECOMPOSITION**\n1.  **Binding Site Topology:** Are the binding sites for CBD, erastin, and DIDS on VDAC1 spatially distinct or overlapping? How do their chemical properties (lipophilicity, reactivity) dictate their engagement mechanisms?\n2.  **Isoform Selectivity Determinants:** What specific structural differences (N-terminal extension, BAK interface, subtle barrel variations) between VDAC1 and VDAC2 dominate ligand selectivity? Is selectivity driven by direct occlusion or by altered allosteric networks?\n3.  **Pharmacological Class Prediction:** Does binding to the N-terminal helix (gating domain) vs. the \u03b2-barrel wall (conductance domain) reliably predict allosteric modulation vs. pore blockade?\n4.  **Feasibility of VDAC2-Sparing Design:** Given high homology, can sufficient selectivity be achieved by targeting VDAC1-unique structural features, or must it rely on differential cofactor (HK-II, BAK) occupancy states?\n\n**Key Variables:** Ligand chemotype (logP, reactive groups), binding site location (helix interface, barrel lumen, vestibule), VDAC isoform sequence/structure divergence, functional readout (channel conductance vs. gating kinetics).\n\n\u2500\u2500\u2500\n**SECTION 2: CLAIMS**\n**CLAIM 1:** CBD, erastin, and DIDS bind to three non-overlapping sites on VDAC1: CBD at the membrane-facing groove near the N-terminal helix, erastin within a \u03b2-barrel lumen pocket (strands 14-19), and DIDS at the pore vestibule (covalent to K12/K20).\n**TYPE:** 1\n**CONFIDENCE:** 0.75\n**MECHANISM:** Distinct ligand physicochemical properties (high logP, moderate polarity, covalent reactivity) drive partitioning into complementary, non-competitive niches on the channel.\n**FALSIFIABLE BY:** Co-crystal/cryo-EM structures showing spatial overlap; competitive binding assays demonstrating mutual displacement.\n\n**CLAIM 2:** The primary determinant for VDAC1-selective ligand design is the 11-residue N-terminal extension of VDAC2, which acts as a steric filter occluding the VDAC1-like CBD/helix interface and remodeling the pore vestibule electrostatics.\n**TYPE:** 1\n**CONFIDENCE:** 0.70\n**MECHANISM:** The extended N-terminus physically blocks access to the lipid-protein interface pocket and alters the local electrostatic potential, reducing affinity for VDAC1-pocket ligands.\n**FALSIFIABLE BY:** Chimeric studies showing swapping the N-terminus swaps selectivity; mutagenesis shortening VDAC2's N-terminus increasing CBD affinity to VDAC1 levels.\n\n**CLAIM 3:** Ligands binding the N-terminal helix (e.g., CBD) primarily modulate voltage-gating kinetics (allosteric), while ligands binding the barrel wall/lumen (e.g., erastin, DIDS) primarily reduce single-channel conductance (pore occlusion).\n**TYPE:** 2\n**CONFIDENCE:** 0.65\n**MECHANISM:** Helix binding stabilizes specific helix conformations that couple to the barrel's global flexibility, altering the free energy landscape for gating; barrel binding directly obstructs the ion conduction pathway.\n**FALSIFIABLE BY:** Single-channel recordings showing CBD alters gating frequency without reducing open-state conductance, while erastin/DIDS reduce unitary conductance.\n\n**CLAIM 4:** Achieving >10-fold VDAC1 selectivity is feasible by targeting the N-terminal helix groove, but achieving complete VDAC2-sparing (<1% cross-reactivity) will require exploiting differential cofactor (HK-II/BAK) occupancy states that allosterically reshape the binding site.\n**TYPE:** 3\n**CONFIDENCE:** 0.60\n**MECHANISM:** High transmembrane homology limits absolute selectivity from static structure alone; dynamic complexes with HK-II (VDAC1) or BAK (VDAC2) create isoform-unique conformational ensembles for ligand discrimination.\n**FALSIFIABLE BY:** Screening compounds against purified VDAC1/VDAC2 in proteoliposomes with/without HK-II or BAK, showing cofactor-dependent selectivity shifts.\n\n\u2500\u2500\u2500\n**SECTION 3: UNKNOWNS**\n1.  High-resolution structures of VDAC2 (apo and ligand-bound) are missing, preventing atomic-level comparison of putative binding pockets.\n2.  Quantitative binding affinities (Kd) of CBD, erastin, and DIDS for VDAC2 are unknown, preventing a precise selectivity ratio calculation.\n3.  The exact conformational state (open/closed) stabilized by CBD binding to the N-terminal helix is unresolved.\n4.  The occupancy state of VDAC1 by HK-II and VDAC2 by BAK in cellular contexts relevant to compound screening is poorly quantified, making *in vitro* selectivity predictions uncertain.\n\n\u2500\u2500\u2500\n**SECTION 4: NEXT STEP**\nDetermine the cryo-EM structure of human VDAC2 in nanodiscs, with and without its N-terminal peptide, to define the steric and electrostatic landscape of its putative ligand-binding sites versus VDAC1.",
      "claims": [
        {
          "statement": "1:** CBD, erastin, and DIDS bind to three non-overlapping sites on VDAC1: CBD at the membrane-facing groove near the N-terminal helix, erastin within a \u03b2-barrel lumen pocket (strands 14-19), and DIDS at the pore vestibule (covalent to K12/K20).",
          "type": 1,
          "confidence": 0.75,
          "mechanism": "Distinct ligand physicochemical properties (high logP, moderate polarity, covalent reactivity) drive partitioning into complementary, non-competitive niches on the channel.",
          "falsifiable_by": "Co-crystal/cryo-EM structures showing spatial overlap; competitive binding assays demonstrating mutual displacement."
        },
        {
          "statement": "2:** The primary determinant for VDAC1-selective ligand design is the 11-residue N-terminal extension of VDAC2, which acts as a steric filter occluding the VDAC1-like CBD/helix interface and remodeling the pore vestibule electrostatics.",
          "type": 1,
          "confidence": 0.7,
          "mechanism": "The extended N-terminus physically blocks access to the lipid-protein interface pocket and alters the local electrostatic potential, reducing affinity for VDAC1-pocket ligands.",
          "falsifiable_by": "Chimeric studies showing swapping the N-terminus swaps selectivity; mutagenesis shortening VDAC2's N-terminus increasing CBD affinity to VDAC1 levels."
        },
        {
          "statement": "3:** Ligands binding the N-terminal helix (e.g., CBD) primarily modulate voltage-gating kinetics (allosteric), while ligands binding the barrel wall/lumen (e.g., erastin, DIDS) primarily reduce single-channel conductance (pore occlusion).",
          "type": 2,
          "confidence": 0.65,
          "mechanism": "Helix binding stabilizes specific helix conformations that couple to the barrel's global flexibility, altering the free energy landscape for gating; barrel binding directly obstructs the ion conduction pathway.",
          "falsifiable_by": "Single-channel recordings showing CBD alters gating frequency without reducing open-state conductance, while erastin/DIDS reduce unitary conductance."
        },
        {
          "statement": "4:** Achieving >10-fold VDAC1 selectivity is feasible by targeting the N-terminal helix groove, but achieving complete VDAC2-sparing (<1% cross-reactivity) will require exploiting differential cofactor (HK-II/BAK) occupancy states that allosterically reshape the binding site.",
          "type": 3,
          "confidence": 0.6,
          "mechanism": "High transmembrane homology limits absolute selectivity from static structure alone; dynamic complexes with HK-II (VDAC1) or BAK (VDAC2) create isoform-unique conformational ensembles for ligand discrimination.",
          "falsifiable_by": "Screening compounds against purified VDAC1/VDAC2 in proteoliposomes with/without HK-II or BAK, showing cofactor-dependent selectivity shifts. \u2500\u2500\u2500 **"
        }
      ]
    }
  ],
  "snapshot": {
    "round_num": 0,
    "jaccard": 0.0903113553113553,
    "cosine": 0.7489520668983459,
    "jsd": 0.3118012687341807,
    "kappa": 0.7299065420560747,
    "type_distribution": {
      "0": 0.0,
      "1": 0.4666666666666667,
      "2": 0.4666666666666667,
      "3": 0.06666666666666667
    },
    "type_01_ratio": 0.4666666666666667,
    "n_claims_per_model": [
      4,
      3,
      1,
      3,
      4
    ]
  },
  "total_calls": 5
}